VacZine Analytics  
MarketVIEW: Cytomegalovirus (CMV) vaccines

Published: August 2014

Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system e.g. HIV, transplants (HSCT) the virus can reactivate can cause disease e.g. pneumonia. CMV infection is also a concern in the neonate after transmission from a pregnant women pre or post partum. Approximately 1 in 150 children is born with a congenital CMV infection and 1 in 750 born with permanent disabilities due to the virus.

This MarketVIEW product is composed of comprehensive MS Excel-based models + summary presentation which forecasts the potential commercial value of Cytomegalovirus vaccines (TX + PX approaches) across major Western and emerging markets to 2030. Each model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. Two forecast scenarios are included based upon the level of populations targeted, differing competitive scenarios which in turn are influenced by vaccine mechanism of action and vaccinee serostatus.

THIS PRODUCT IS A SUMMARY PRESENTATION + TWO MODELS

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV014 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2014 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains